Earnings Briefs: Biogen, Celgene, Actelion, Cubist
Executive Summary
Biogen gains approval for its latest MS treatment in the EU; Celgene pushes ahead with Otezla, despite soft launch; Actelion looking outside PAH for business development; Cubist developing patient access program for Sivextro.